Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ516MR)

This product GTTS-WQ516MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001250.6
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	958
UniProt ID	P25942

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ516MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ5654MR	IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CDX-011
GTTS-WQ6104MR	IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CNTO-1959
GTTS-WQ8417MR	IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HSP90mab
GTTS-WQ3144MR	IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	APT070
GTTS-WQ1808MR	IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ADCT-402
GTTS-WQ6444MR	IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	CT-P23
GTTS-WQ11831MR	IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MK-4280
GTTS-WQ15985MR	IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ZTS-00521505

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST